Clinical Trial Update: ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ILKN421H plus pembrolizumab for locally advanced or metastatic non-small cell lung cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ILKN421H (ILKN421H)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: iLeukon Therapeutics, Inc. | Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: NOT_YET_RECRUITING